{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:04:47Z","timestamp":1783105487394,"version":"3.54.6"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T00:00:00Z","timestamp":1631318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,24]]},"DOI":"10.1093\/rheumatology\/keab698","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:23:24Z","timestamp":1631190204000},"page":"e22-e24","source":"Crossref","is-referenced-by-count":4,"title":["Clinical and serological resolution of pembrolizumab associated Sj\u00f6gren\u2019s syndrome: long-term follow-up"],"prefix":"10.1093","volume":"61","author":[{"given":"Hadleigh J","family":"Clark","sequence":"first","affiliation":[{"name":"Oral Medicine Subservice, Auckland Regional Hospital & Specialist Dentistry, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C C","family":"Fong","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Regional Blood and Cancer Service, Auckland District Health Board, Auckland, New Zealand"},{"name":"Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine P L","family":"Ng","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"},{"name":"Rheumatology Department, Waitemata District Health Board, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,11]]},"reference":[{"key":"2022010903213751000_keab698-B1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022010903213751000_keab698-B2","first-page":"114","article-title":"Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37(Suppl 118","author":"Ramos-Casals","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022010903213751000_keab698-B3","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca syndrome induced by immune checkpoint inhibitor therapy: ptimal management still pending","volume":"25","author":"Ortiz Brugu\u00e9s","year":"2020","journal-title":"Oncologist"},{"key":"2022010903213751000_keab698-B4","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"2022010903213751000_keab698-B5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"2022010903213751000_keab698-B6","doi-asserted-by":"crossref","first-page":"108497","DOI":"10.1016\/j.clim.2020.108497","article-title":"Sicca syndrome following immune checkpoint inhibition","volume":"217","author":"Mavragani","year":"2020","journal-title":"Clin Immunol"},{"key":"2022010903213751000_keab698-B7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40425-018-0429-4","article-title":"A severe case of neuro-Sj\u00f6gren\u2019s syndrome induced by pembrolizumab","volume":"6","author":"Ghosn","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2022010903213751000_keab698-B8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab698\/40521402\/keab698.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/1\/e22\/41928971\/keab698.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/1\/e22\/41928971\/keab698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T03:25:46Z","timestamp":1641698746000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/1\/e22\/6368710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,11]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,9,11]]},"published-print":{"date-parts":[[2021,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab698","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,9,11]]}}}